Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial–mesenchymal transition process

Use of paclitaxel as monotherapy or in combination with other therapeutic agents is a widely employed front‐line chemotherapeutic strategy for cervical cancer. However, previous reports have shown that approximately 70% of the patients with cervical cancer develop resistance to paclitaxel. Epithelia...

Ausführliche Beschreibung